Sclerosis multiplex (SM): vizsgálatok itt: Románia
9 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 11.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleA Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
- Where
- Brasov, Constanța, Târgu Mureş
- Életkor
- 18 év to 60 év
- People
- 705 worldwide
- Run by
- Zenas BioPharma (USA), LLC
See details and how to joinNCT07067463 · EU 2025-524316-11-00 - 3. fázisTaking peopleA Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis
- Where
- Constanța, Radauti, jud. Suceava
- Életkor
- 18 év to 60 év
- People
- 990 worldwide
- Run by
- Zenas BioPharma (USA), LLC
See details and how to joinNCT07299019 · EU 2025-524322-18-00 - 3. fázisTaking peopleEfficacy and safety study of frexalimab (SAR441344) in adults with relapsing forms of multiple sclerosis
- Where
- Campulung
- Életkor
- 18 év to 64 év
- People
- 386 worldwide
- Run by
- Sanofi-Aventis Recherche & Developpement
See details and how to join2023-504358-36-00 · EU 2023-504358-36-00 - 2. fázisTaking peopleMulticenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients with Progressive Multiple Sclerosis
- Where
- Cluj-Napoca
- Életkor
- 18 év to 64 év
- People
- 230 worldwide
- Run by
- Immunic AG
See details and how to joinNCT05054140 · EU 2024-514617-35-00 - 3. fázisTaking peopleA Randomized, Double-blind, Study to Demonstrate Pharmacokinetic Similarity, and Evaluate Safety, Immunogenicity, Pharmacodynamics and Clinical Effects between ABP 692 and Ocrevus® (Ocrelizumab) in Subjects with Relapsing-remitting Multiple Sclerosis
- Where
- Bucharest, Cluj-Napoca
- Életkor
- 18 év to 64 év
- People
- 125 worldwide
- Run by
- Amgen Inc.
See details and how to join2024-512914-16-00 · EU 2024-512914-16-00 - 3. fázisTaking peopleA Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
- Where
- Bucharest, Campulung Muscel, Constanța
- Életkor
- 18 év to 65 év
- People
- 1275 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07225504 - 3. fázisTaking peopleEfficacy and safety of ofatumumab and siponimod compared to fingolimod in pediatric patients with multiple sclerosis
- Where
- Bucharest
- Életkor
- Up to 17 év
- People
- 64 worldwide
- Run by
- Novartis Pharma AG
See details and how to join2024-511686-11-00 · EU 2024-511686-11-00 - 3. fázisTaking peopleStudy to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis
- Where
- Bucharest
- Életkor
- 10 év to 17 év
- People
- 194 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT06408259 · EU 2022-501332-42-00 - 3. fázisTaking peopleA clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosis
- Where
- Bucharest, Campulung, Constanța
- Életkor
- 18 év and over
- People
- 677 worldwide
- Run by
- Novartis Pharma AG
See details and how to join2025-521546-23-00 · EU 2025-521546-23-00